Hepion Pharmaceuticals, Inc. (HEPA)

Market Cap	697.22K -53.7%
Revenue (ttm)	n/a
Net Income	-8.28M
EPS	-0.88
Shares Out	11.62M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,561
Average Volume	20,767
Open	0.0605
Previous Close	0.0605
Day's Range	0.0600 - 0.0729
52-Week Range	0.0330 - 0.9890
Beta	1.94
RSI	55.24
Earnings Date	Mar 27, 2026

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 2
• Stock Exchange: OTCMKTS
• Ticker Symbol: HEPA